scholarly journals Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

Science ◽  
2015 ◽  
Vol 347 (6219) ◽  
pp. 273-277 ◽  
Author(s):  
R. L. Flynn ◽  
K. E. Cox ◽  
M. Jeitany ◽  
H. Wakimoto ◽  
A. R. Bryll ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Alternative Lengthening Of Telomeres ◽  
Alternative Lengthening

scholarly journals SETDB1-dependent heterochromatin stimulates alternative lengthening of telomeres

2019 ◽  
Vol 5 (5) ◽  
pp. eaav3673 ◽  
Author(s):  
Mathilde Gauchier ◽  
Sophie Kan ◽  
Amandine Barral ◽  
Sandrine Sauzet ◽  
Eneritz Agirre ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Therapeutic Approach ◽  
Quantitative Proteomics ◽  
Opposite Effect ◽  
Transcriptional Elongation ◽  
Alternative Lengthening Of Telomeres ◽  
Heterochromatin Formation ◽  
Alternative Lengthening ◽  
Telomeric Heterochromatin ◽  
Prevailing View

Alternative lengthening of telomeres, or ALT, is a recombination-based process that maintains telomeres to render some cancer cells immortal. The prevailing view is that ALT is inhibited by heterochromatin because heterochromatin prevents recombination. To test this model, we used telomere-specific quantitative proteomics on cells with heterochromatin deficiencies. In contrast to expectations, we found that ALT does not result from a lack of heterochromatin; rather, ALT is a consequence of heterochromatin formation at telomeres, which is seeded by the histone methyltransferase SETDB1. Heterochromatin stimulates transcriptional elongation at telomeres together with the recruitment of recombination factors, while disrupting heterochromatin had the opposite effect. Consistently, loss of SETDB1, disrupts telomeric heterochromatin and abrogates ALT. Thus, inhibiting telomeric heterochromatin formation in ALT cells might offer a new therapeutic approach to cancer treatment.

scholarly journals Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells

2019 ◽  
Vol 17 (12) ◽  
pp. 2480-2491 ◽  
Author(s):  
Mindy K. Graham ◽  
Jiyoung Kim ◽  
Joseph Da ◽  
Jacqueline A. Brosnan-Cashman ◽  
Anthony Rizzo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Prostate Cancer Cells ◽  
Alternative Lengthening Of Telomeres ◽  
Functional Loss ◽  
Alternative Lengthening

scholarly journals Oncogenic herpesvirus KSHV triggers hallmarks of alternative lengthening of telomeres

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Timothy P. Lippert ◽  
Paulina Marzec ◽  
Aurora I. Idilli ◽  
Grzegorz Sarek ◽  
Aleksandra Vancevska ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Cell Lines ◽  
Telomere Maintenance ◽  
Alternative Lengthening Of Telomeres ◽  
Telomere Shortening ◽  
Alternative Lengthening ◽  
A Cell ◽  
Infected Cells ◽  
Break Induced Replication ◽  
Alt Activity

AbstractTo achieve replicative immortality, cancer cells must activate telomere maintenance mechanisms to prevent telomere shortening. ~85% of cancers circumvent telomeric attrition by re-expressing telomerase, while the remaining ~15% of cancers induce alternative lengthening of telomeres (ALT), which relies on break-induced replication (BIR) and telomere recombination. Although ALT tumours were first reported over 20 years ago, the mechanism of ALT induction remains unclear and no study to date has described a cell-based model that permits the induction of ALT. Here, we demonstrate that infection with Kaposi’s sarcoma herpesvirus (KSHV) induces sustained acquisition of ALT-like features in previously non-ALT cell lines. KSHV-infected cells acquire hallmarks of ALT activity that are also observed in KSHV-associated tumour biopsies. Down-regulating BIR impairs KSHV latency, suggesting that KSHV co-opts ALT for viral functionality. This study uncovers KSHV infection as a means to study telomere maintenance by ALT and reveals features of ALT in KSHV-associated tumours.

scholarly journals Cancer cells with alternative lengthening of telomeres do not display a general hypersensitivity to ATR inhibition

2016 ◽  
Author(s):  
Katharina I. Deeg ◽  
Inn Chung ◽  
Caroline Bauer ◽  
Karsten Rippe
Keyword(s):  
Cell Viability ◽  
Cancer Cells ◽  
Cell Lines ◽  
Ataxia Telangiectasia ◽  
Telomere Maintenance ◽  
Alternative Lengthening Of Telomeres ◽  
Isogenic Cell Line ◽  
Alternative Lengthening ◽  
Cellular Immortality ◽  
Proliferation Potential

AbstractTelomere maintenance is a hallmark of cancer as it provides cancer cells with cellular immortality. A significant fraction of tumors uses the alternative lengthening of telomeres (ALT) pathway to elongate their telomeres and to gain an unlimited proliferation potential. Since the ALT pathway is unique to cancer cells, it represents a potentially valuable, currently unexploited target for anticancer therapies. Recently, it was proposed that ALT renders cells hypersensitive to ataxia telangiectasia-and RAD3-related (ATR) protein inhibitors (Flynn et al., Science 347, 273). Here, we measured the response of various ALT or telomerase positive cell lines to the ATR inhibitor VE-821. In addition, we compared the effect of the inhibitor on cell viability in an isogenic cell line, in which ALT was active or suppressed. In these experiments a general ATR inhibitor sensitivity of cells with ALT could not be confirmed. We rather propose that the observed variations in sensitivity reflect differences between cell lines that are unrelated to ALT.

scholarly journals Alternative lengthening of telomeres in hTERT-inhibited laryngeal cancer cells

2010 ◽  
Vol 101 (8) ◽  
pp. 1769-1776 ◽  
Author(s):  
Wei Chen ◽  
Bo-Kui Xiao ◽  
Jun-Ping Liu ◽  
Shi-Ming Chen ◽  
Ze-Zhang Tao
Keyword(s):  
Cancer Cells ◽  
Laryngeal Cancer ◽  
Alternative Lengthening Of Telomeres ◽  
Alternative Lengthening

scholarly journals Morphogenesis of giant telomeric nuclear bodies in cancer cells with alternative lengthening of telomeres

2019 ◽  
Author(s):  
Yuu Arimasu ◽  
Masachika Fujiwara ◽  
Jun Ishii ◽  
Tomohiro Chiba ◽  
Yuichi Terado ◽  
...  
Keyword(s):  
Homologous Recombination ◽  
Cancer Cells ◽  
Super Resolution ◽  
Maximum Size ◽  
Nuclear Bodies ◽  
Dna Repeats ◽  
Metaphase Chromosomes ◽  
Interphase Nuclei ◽  
Alternative Lengthening Of Telomeres ◽  
Alternative Lengthening

AbstractSome cancer cells lengthen their telomeres by alternative lengthening of telomeres (ALT); these are referred to as ALT cancer cells and do not express telomerase. The ALT mechanism involves the elongation of telomeric DNA repeats by homologous recombination. In interphase nuclei of ALT cancer cells, giant telomeres can be specifically observed by fluorescencein situhybridization (FISH) to detect telomeric repeats, and they are co-localized with promyelocytic-leukemia nuclear-bodies (PML-NBs). However, it how large telomeres specific to ALT and how they form a structural relation with PML-NBs. We refer to giant telomeres specific to interphase ALT cancer cells giant-telomeric nuclear-bodies (GT-NBs). To quantitatively define GT-NBs, we performed telomeric FISH of both interphase nuclei and metaphase chromosomes and analyzed telomere sizes by integrated FISH signals. The distributions of telomere sizes in telomerase-positive cells were similar in interphase nuclei and chromosomes. However, the distribution of telomere sizes in ALT cancer cells differed between interphase nuclei and chromosomes. Giant telomeres that were larger than those at chromosomal ends were only observed in interphase nuclei of ALT cancer cells. Accordingly, GT-NBs could be quantitatively defined as larger than the maximum size of telomeres at chromosomal ends. Furthermore, ALT cancer cells demonstrated fewer telomeric signals in interphase nuclei than in chromosomes. These findings indicate that GT-NBs could be formed by the aggregation of two or more telomeres at chromosomal ends. Furthermore, super-resolution microscopy showed that GT-NBs contain one or two PML-NBs. GT-NBs are considered aggregates of telomeres and could contain multiple sites of homologous recombination accompanied by PML-NBs. These findings may contribute to the development of therapeutic approaches for ALT cancer. (251 words)

Sign in / Sign up

Export Citation Format

Share Document